Pieris Pharmaceuticals (PIRS) News and press releases

US crude oil futures traded slightly lower this morning on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Here's a roundup of top developments in the biotech space over the last 24 hours:

Pieris Pharmaceuticals (NASDAQ:PIRS) reported its Q1 earnings results on Wednesday, May 11, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Pieris Pharmaceuticals (NASDAQ:PIRS) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.11) by 36.36 percent. This is unchanged from the same period last year. The company

Companies Reporting Before The Bell • Great Elm Capital (NASDAQ:GECC) is expected to report earnings for its first quarter.

Pieris Pharmaceuticals (NASDAQ:PIRS) is set to give its latest quarterly earnings report on Wednesday, 2022-05-11. Here's what investors need to know before the announcement. Analysts estimate that Pieris Pharmaceuticals will report an earnings per share (EPS) of $-0.11.

According to Benzinga Pro data, during Q4, Pieris Pharmaceuticals (NASDAQ:PIRS) posted sales of $8.44 million. Earnings were up 42.36%, but Pieris Pharmaceuticals still reported an overall loss of $9.53 million.

Pieris Pharmaceuticals (NASDAQ:PIRS) reported its Q4 earnings results on Tuesday, March 1, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter.

Analysts and brokerage firms often use ratings when they issue stock recommendations to stock traders. Analysts arrive at stock ratings by researching public financial statements, communicating with executives and customers and following industry trends.

BOSTON, MA / ACCESSWIRE / May 18, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for

Company To Host an Investor Conference Call On Wednesday, May 11, 2022 At 8:00 Am EDTBOSTON, MA / ACCESSWIRE / May 11, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing

BOSTON, MA / ACCESSWIRE / May 4, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for

Allan Reine joins the Board as independent Non-Executive Director Brings significant experience as CFO of NASDAQ-listed biotechs, where he helped raise over $700 million Over 20 years in the biotechnology industry with

COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON TUESDAY, MARCH 1, 2022 AT 8:00 AM ESTInitiated efficacy part of phase 2a study of PRS-060/AZD1402; expected topline readout this yearDosed first patient in phase 2 gastric

BOSTON, MA / ACCESSWIRE / February 23, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform